Our data suggest that peripheral blood analysis may provide valuable insights into predicting responses to PD-1–targeted therapies in endometrial cancer and warrant further studies on identification of peripheral blood biomarkers using larger and independent patient cohorts with attention to immune alterations within tumoral compartment. The gene discussed is PDCD1; the disease is endometrial cancer.